Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-04-30

Molecular and Clinical Neuropathology of Huntington's disease and spinocerebellar ataxia

Objectif

To develop an understanding of the molecular pathology of Huntington's disease (HD) and neurodegenerative diseases caused by CAG expansion thereby laying the ground work for the development of therapeutic strategies.

This will involve the identification of the normal function of the huntingtin (htt) protein, the changes brought about by a CAG expansion, the generation of cellular and animal model systems of HD and the initiation of a parallel analysis of Machado Joseph disease (SCA3).

A number of inherited, late onset, neurodegenerative disorders have been described which show anticipation when the respective gene is inherited through the male line. The neurodegeneration is selective, differs between the diseases and its biochemical basis is unknown. Isolation of the genes for five of these diseases: HD, SBMA, SCA1, DRPLA and MJD (SCA3) has shown the underlying mutation to be a CAG expansion. In all cases, the identification of the mutation has led to accurate diagnostic tests, and an understanding of the molecular basis of some of the genetic features, but it has done little to uncover the chain of events leading to the observed neuropathology. In all cases the repeat lies within the coding region and codes for a stretch of polyglutamine residues (polygln). It is particularly fascinating that these proteins can tolerate such a wide variation in the polygln size within the normal range, yet the further addition of a few residues causes the disease, and, that this apparently universal mutation, when present in different disease genes causes such strikingly selective cell death. An understanding of this process is central to the eventual design of methods to prevent or delay the onset or interrupt the progression of these diseases.
We plan to carry out a comprehensive analysis of the molecular basis of HD and MJD. A unique set of complementary resources, in the form of antibodies and clones has already been generated by the partners. The normal function of huntingtin (htt), its cellular interactions and the mechanism by which the polyglutamine expansion changes this function must be established. In situ hybridisation, immunohistochemistry, immunoelectron microscopy and western analysis will be used to determine the cellular localisation of htt and SCA3 proteins and quantify their expression in normal and affected brains. An interspecies comparative sequence analysis of htt and its homologues will be used to identify functional domains. Htt will be expressed in vitro to allow the identification of interacting proteins. Cellular and animal models of HD will be developed using cDNA and genomic constructs carrying expansions, both to produce transgenic mice and for the introduction into neuronal cell lines. Such models are essential to study the disease mechanism and to allow the future testing of therapeutic agents that may block the progression of these devastating diseases for which there are no effective therapies.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN. Voir: Le vocabulaire scientifique européen.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Programme(s)

Programmes de financement pluriannuels qui définissent les priorités de l’UE en matière de recherche et d’innovation.

Thème(s)

Les appels à propositions sont divisés en thèmes. Un thème définit un sujet ou un domaine spécifique dans le cadre duquel les candidats peuvent soumettre des propositions. La description d’un thème comprend sa portée spécifique et l’impact attendu du projet financé.

Appel à propositions

Procédure par laquelle les candidats sont invités à soumettre des propositions de projet en vue de bénéficier d’un financement de l’UE.

Données non disponibles

Régime de financement

Régime de financement (ou «type d’action») à l’intérieur d’un programme présentant des caractéristiques communes. Le régime de financement précise le champ d’application de ce qui est financé, le taux de remboursement, les critères d’évaluation spécifiques pour bénéficier du financement et les formes simplifiées de couverture des coûts, telles que les montants forfaitaires.

CSC - Cost-sharing contracts

Coordinateur

United Medical and Dental Schools of Guy's and St Thomas's Hospitals
Contribution de l’UE
Aucune donnée
Adresse
8th Floor Guy's Tower
SE1 9RT London
Royaume-Uni

Voir sur la carte

Coût total

Les coûts totaux encourus par l’organisation concernée pour participer au projet, y compris les coûts directs et indirects. Ce montant est un sous-ensemble du budget global du projet.

Aucune donnée

Participants (4)

Mon livret 0 0